Kala Pharmaceuticals Q3 EPS $(3.41) Misses $(2.15) Estimate
Portfolio Pulse from Benzinga Newsdesk
Kala Pharmaceuticals (NASDAQ:KALA) reported a Q3 EPS loss of $(3.41), missing the consensus estimate of $(2.15) by 58.6%. However, this represents a 61.77% improvement from the $(8.92) per share loss in the same quarter last year.
November 13, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Kala Pharmaceuticals reported a larger-than-expected Q3 loss per share of $(3.41), which did not meet the $(2.15) estimate, but showed significant year-over-year improvement.
The reported EPS miss is likely to negatively impact investor sentiment in the short term, as the loss was significantly higher than expected. However, the improvement from the previous year's loss may provide some positive context.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100